Ceribell
Manufacturing · California, United States · 201-500 Employees
View Company Info for Free
Overview
Headquarters
360 N Pastoria Ave, Sunnyvale, Californi...Phone Number
(800) 436-0826Website
www.ceribell.comRevenue
$95.1 MillionStock Symbol
CBLLIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
3
1
1
1
1
1
About Ceribell
Ceribell is a venture-backed medical device start-up company founded in 2014 by two faculty members at Stanford University who were frustrated by the conventional EEG systems. To meet the clinical unmet needs, Ceribell has developed a point-of-care EEG system that makes the diagnosis of neurological patients drastically more efficient. Ceribell is focused on making EEG widely accessible, more efficient, and more cost-effective to improve the diagnosis and treatment of patients at risk for seizure. Weve created and validated an FDA cleared EEG system that does not require an EEG tech to do a lengthy setup or a long wait for a specialist to interpret the initial results.Explore more
Ceribell Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Ceribell your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Earning: See what the market has to say on Ceribell recently announced quarterly report
Product Launch: Get notified when Ceribell launches new products
Website visits: Recent activity has been detected on your website
Check out if Ceribell is spiking on competitors!
Ceribell, which may be a good buyer, showed buying intent in Masked Content Topic
Congratulate Masked Content for being promoted to Masked Content at Ceribell
Funding: Get notified immidiatlly once Ceribell has new funding data
Click to see if Ceribell had a recent Job posting/layoffs
Check if Ceribell has recently received funding, and reach out quickly before it becomes old news!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 2 more new buyers
Compare Similar Companies to Ceribell
Compare insights from companies similar to Ceribell, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Ceribell is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Ceribell is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Ceribell.
Ceribell financials insights
Gather financial insights about Ceribell, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2017
Series A
$13M
2018
Series B
$35M
2020
Debt
$20M
2021
Series C
$103M
Ceribell Tech Stack
A closer look at the technologies used by Ceribell
See more technologies
Most Recent Scoops
Open Position
Open Position
Project
Ceribell has received FDA clearance for a delirium monitoring indication and has initiated a pilot program, with a formal launch targeted for Q4 2025 or Q1 2026, making it the first and only delirium algorithm of its kind. This new indication adds approximately $1 billion to the US total addressable market.
Project
Ceribell has announced the launch of its FDA-cleared seizure detection algorithm and new infant form factor for neonates and children, making it the first and only seizure detection algorithm cleared for this patient population. The launch, which occurred in Q1 of this year, expands the company's total addressable market by approximately $400 million.
Project
Ceribell News & Media
Ceribell CTO sells shares to cover RSU taxes | CBLL Insider Trading - Stock Titan
Ceribell CTO Raymond Woo sold 1,966 shares at $18.00 to cover tax withholding from RSU vesting, retaining 195,682 shares after this routine insider transaction.Ceribell to Participate in the William Blair 46th Annual Growth Stock Conference
SUNNYVALE, Calif., May 20, 2026 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that Jane Chao, Ph.D., CEO and Co-founder, will present at the upcoming William Blair 46th Annual Growth Stock Conference in Chicago. The presentation will take place on Wednesday, June 3, 2026, at 9:20 a.m. Pacific Daylight Time / 11:20 a.m. Central DayliCeriBell, Inc. (CBLL) Presents at Bank of America Global Healthcare Conference 2026 Transcript
CeriBell, Inc. (CBLL) Bank of America Global Healthcare Conference 2026 May 13, 2026 6:40 PM EDTCompany ParticipantsXingjuan Chao - Co-Founder, President,...CeriBell Q1 Earnings Call Highlights
CeriBell (NASDAQ:CBLL) reported first-quarter revenue growth of 29% and raised its full-year outlook, as management cited higher usage of its seizure monitoring system and the company’s strongest quarter of net new hospital additions since becoming public. On the company’s earnings call, Co-founder
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Ceribell
Sign Up For FreeTo access detailed company insights
Ceribell is a venture-backed medical device start-up company founded in 2014 by two faculty members at Stanford University who were frustrated by the conventional EEG systems. To meet the clinical unmet needs, Ceribell has developed a point-of-care EEG system that makes the diagnosis of neurological patients drastically more efficient. Ceribell is... Read More
